Terms: = Ovarian cancer AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Prognosis
411 results:
1. [Gonadoblastoma: Clinicopathological study and literature review of 3 cases].
Bao ML; Li X; Chen G; Li H; Chen W; Li HX
Zhonghua Nan Ke Xue; 2023 Jul; 29(7):634-638. PubMed ID: 38619412
[TBL] [Abstract] [Full Text] [Related]
2. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
[TBL] [Abstract] [Full Text] [Related]
3. A clinicopathological study about the epidemiology of granulosa cell tumors in Lebanon.
Yaacoub S; Hajj L; Khairallah A
BMC Cancer; 2024 Mar; 24(1):309. PubMed ID: 38448917
[TBL] [Abstract] [Full Text] [Related]
4. The Role of Lymphovascular Space Invasion and Cytology in the prognosis of Endometrial cancer.
Ozdemir CY; Arioz DT; Celik F; Cicekli N; Chkhikvadze M; Bilir F; Yılmaz S; Vatansever N
Discov Med; 2024 Feb; 36(181):366-371. PubMed ID: 38409841
[TBL] [Abstract] [Full Text] [Related]
5. The IGF-PAPP-A-Stanniocalcin Axis in Serum and Ascites Associates with prognosis in Patients with ovarian cancer.
Hjortebjerg R; Høgdall C; Hansen KH; Høgdall E; Frystyk J
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396692
[TBL] [Abstract] [Full Text] [Related]
6. prognosis and conditional survival among women with newly diagnosed ovarian cancer.
Szamreta EA; Monberg MJ; Desai KD; Li Y; Othus M
Gynecol Oncol; 2024 Jan; 180():170-177. PubMed ID: 38211405
[TBL] [Abstract] [Full Text] [Related]
7. Agricultural exposure and risk of ovarian cancer in the AGRIculture and cancer (AGRICAN) cohort.
Renier M; Hippert J; Louis-Bastien W; Tual S; Meryet-Figuiere M; Vigneron N; Marcotullio E; Baldi I; Lebailly P;
Occup Environ Med; 2024 Feb; 81(2):75-83. PubMed ID: 38199811
[TBL] [Abstract] [Full Text] [Related]
8. TGF-β-regulated different iron metabolism processes in the development and cisplatin resistance of ovarian cancer.
Wu J; Liao Q; Zhang LI; Wu S; Liu Z
Oncol Res; 2023; 32(2):373-391. PubMed ID: 38186569
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
[TBL] [Abstract] [Full Text] [Related]
10. Safety of fertility-sparing surgery in young women with stage I endometrioid epithelial and mucinous ovarian cancer: A population-based analysis.
Li J; Qiao H; Liu Y; Huang C; Cheng A; Lin Z; Wang L; Lu H
Eur J Surg Oncol; 2024 Jan; 50(1):107276. PubMed ID: 38064863
[TBL] [Abstract] [Full Text] [Related]
11. High-grade serous ovarian carcinoma, the "Achiles' hill" for clinicians and molecular biologists: a molecular insight.
Bhattacharya R; Ghosh A; Mukhopadhyay S
Mol Biol Rep; 2023 Nov; 50(11):9511-9519. PubMed ID: 37737967
[TBL] [Abstract] [Full Text] [Related]
12. A spectroscopic liquid biopsy for the earlier detection of multiple cancer types.
Cameron JM; Sala A; Antoniou G; Brennan PM; Butler HJ; Conn JJA; Connal S; Curran T; Hegarty MG; McHardy RG; Orringer D; Palmer DS; Smith BR; Baker MJ
Br J Cancer; 2023 Nov; 129(10):1658-1666. PubMed ID: 37717120
[TBL] [Abstract] [Full Text] [Related]
13. Time-Dependent Changes in Risk of Progression During Use of Bevacizumab for ovarian cancer.
Takamatsu S; Nakai H; Yamaguchi K; Hamanishi J; Mandai M; Matsumura N
JAMA Netw Open; 2023 Aug; 6(8):e2326834. PubMed ID: 37531111
[TBL] [Abstract] [Full Text] [Related]
14. Noninvasive early differential diagnosis and progression monitoring of ovarian cancer using the copy number alterations of plasma cell-free DNA.
Chen L; Ma R; Luo C; Xie Q; Ning X; Sun K; Meng F; Zhou M; Sun J
Transl Res; 2023 Dec; 262():12-24. PubMed ID: 37499745
[TBL] [Abstract] [Full Text] [Related]
15. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R).
Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ
J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300
[TBL] [Abstract] [Full Text] [Related]
16. High Expression of MRE11A Is Associated with Shorter Survival and a Higher Risk of Death in CRC Patients.
Azambuja DB; E Gloria HC; Montenegro GES; Kalil AN; Hoffmann JS; Leguisamo NM; Saffi J
Genes (Basel); 2023 Jun; 14(6):. PubMed ID: 37372450
[TBL] [Abstract] [Full Text] [Related]
17. Hsp90 is a potential risk factor for ovarian cancer prognosis: an evidence of a Chinese clinical center.
Duan C; Li K; Pan X; Wei Z; Xiao L
BMC Cancer; 2023 May; 23(1):489. PubMed ID: 37259027
[TBL] [Abstract] [Full Text] [Related]
18. Relative survival analysis of gynecological cancers in an urban district of Shanghai during 2002-2013.
Jiang YF; Jiang Y; Bi JH; Zhang Y; Zheng WW; Zhou XH; Wu J; Yuan HY; Zhao WS; Xiang YB
Cancer Epidemiol; 2023 Jun; 84():102355. PubMed ID: 36989956
[TBL] [Abstract] [Full Text] [Related]
19. De novo myeloid sarcoma mimicking gynecological tumors: a retrospective case series of eight patients.
Gu Y; Zheng H; Mo S; Guo T; Chen L; Yang J; Xiang Y
BMC Womens Health; 2023 Mar; 23(1):141. PubMed ID: 36978050
[TBL] [Abstract] [Full Text] [Related]
20. Comparison of older and younger patients with ovarian cancer: A post hoc study (JGOG3016-A3) of the treatment strength and prognostic outcomes of conventional or dose-dense chemotherapy.
Itani Y; Sakai H; Hamano T; Asai-Sato M; Futagami M; Fujimura M; Aoki Y; Suzuki N; Yoshida Y; Enomoto T
J Obstet Gynaecol Res; 2023 May; 49(5):1400-1411. PubMed ID: 36859635
[TBL] [Abstract] [Full Text] [Related]
[Next]
